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raltegravir (RAL) while having a viral load (VL) ≤50 cop-
ies/mL in the clinical setting.
Study design Treatment-experienced HIV 1-infected 
patients enrolled in the ICONA Foundation Study cohort 
were included if they switched their current regimen to 
DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Differ-
ent definitions of virological failure (VF) and treatment 
failure (TF) were employed. Kaplan–Meier curves and Cox 
regression models were performed to estimate time to event 
probability.
Results We included 72 HIV-infected patients, 22 (31%) of 
these were female, 31 (43%) men who have sex with men 
(MSM) amd 15 (21%) had hepatitis co-infections. Median 
age was 44 (IQR: 35-50) years amd CD4 count was 389 
(IQR 283-606) cells/mmc. Median follow-up time for 
TF was 24 (IQR 9–31) months. Twenty-five discontinu-
ations occurred (60% simplifications); only 2 (8%) were 
toxicity-driven (lipid elevations). The probability of VF 
(confirmed VL >50 copies/mL) was estimated at 7% [95% 
confidence interval (CI) 1–13%] by 12 and 9% (95% CI 
2–16%) by 24 months. When considering TF, we found a 
probability of stop/intensification/single VL > 200 copies/
mL of 13% (95% CI 1–17%) and 22% (95% CI 11–33%) 
by 12 and 24 months. Female gender (adjusted rela-
tive hazard, ARH = 0.10; 95% CI 0.01–0.74; p = 0.024) 
and older age (AHR = 0.50 per 10 years older; 95% CI 
0.25–0.99; p = 0.045) were associated with a lower risk of 
TF. A previous PI failure was strongly associated with TF 
(AHR = 52.6, 95% CI 3.6–779; p = 0.004).
Conclusions DRV/r + RAL is a valuable NRTI-sparing 
option, especially in female and older patients, with a rel-
atively low risk of VF and good tolerability after 2 years 
since start in an ART-experienced population. However, 
previous PI-failure should be a limiting factor for this 
strategy.
Abstract 
Background Nucleos(t)ide reverse transcriptase inhibitors 
(NRTI) toxicity may represent a threat for long-term suc-
cess of combined antiretroviral therapy. Some studies have 
suggested a possible improvement of NRTI-related toxicity 
after switching to NRTI-sparing regimens.
Objectives We aimed to explore the efficacy and toler-
ability of switching to darunavir/ritonavir (DRV/r) plus 
 * Giordano Madeddu 
 giordano@uniss.it
1
 Department of Clinical and Experimental Medicine, Unit 
of Infectious Diseases, University of Sassari, Viale San Pietro 
8, 07100 Sassari, Italy
2
 Infectious Diseases Unit, DIBIC Luigi Sacco, University 
of Milan, Milan, Italy
3
 Department of Infection and Population Health, Division 
of Population Health, Hampstead Campus, University 
College London, London, UK
4
 Catholic University of the Sacred Heart, Milan, Unit 
of Infectious Diseases, Agostino Gemelli Polyclinic 
Foundation, Rome, Italy
5
 Unit of Infectious Diseases, Department of Medical Sciences, 
University of Turin, Turin, Italy
6
 Infectious Diseases Department, San Raffaele Scientific 
Institute, Università vita e salute, Milan, Italy
7
 Division of Infectious Diseases, Department of Medical 
Biotechnologies, University of Siena and Siena University 
Hospital, Siena, Italy
8
 Unit of Infectious Diseases, IRCCS San Martino Hospital-
IST, Genoa, Italy
9
 Clinical Department, National Institute of Infectious Diseases 
‘Lazzaro Spallanzani’, Rome, Italy
G. Madeddu et al.
1 3
Keywords Darunavir/ritonavir · Raltegravir · Efficacy · 
Tolerability · Antiretroviral therapy · NRTI-sparing 
regimen
Background
Nucleos(t)ide reverse transcriptase inhibitors (NRTI) tox-
icity may represent a threat for long-term success of com-
bined antiretroviral therapy (cART) [1–3]. Some studies 
have suggested a possible improvement of NRTI-related 
toxicity after switching to NRTI-sparing or single NRTI-
including regimens [4–6]. In a recent study conducted in 
patients receiving a successful multidrug salvage regimen 
with at least two active drugs including a boosted protease 
inhibitor (PI), the withdrawal of NRTI was safe [7]. Two 
NRTI plus a third drug, a PI, an integrase inhibitor (INI) 
or non-nucleoside reverse transcriptase inhibitor (NNRTI) 
still represent the cornerstone for cART initiation in naïve 
patients, and the International and National treatment 
Guidelines do not recommended NRTI-sparing regimens in 
the first-line [8–11].
Although most studies were conducted in the scenario of 
antiretroviral-naïve patients, in clinical practice, this NRTI-
sparing regimen is being employed in different strategies 
(salvage, simplification, switching). Other studies suggest 
that the combination is indeed widely used, at least in Spain 
and Italy [7, 12–14]. A recent study by Calza et al. showed 
that in 82 virologically suppressed patients without history 
of PI failure the combination of RAL + DRV/r was capable 
of maintaining a virologic success in more than 92.7% of 
cases at 48 weeks with a significant improvement of lipid 
profile and reduction of tubular proteinuria [15].
Objectives
In this analysis, we aimed to investigate the risk of viro-
logical failure (VF), and tolerability of switching to DRV/r 
plus RAL while having a viral load (VL) ≤50 copies/mL in 
an unselected population from the real life setting.
Study design
Treatment experienced HIV-1-infected patients enrolled in 
the ICONA (Italian Cohort Naïve Antiretrovirals) Foun-
dation Study cohort were included in this analysis if they 
switched their current regimen to DRV/r + RAL with an 
HIV-RNA ≤ 50 copies/mL (baseline). No patient had pre-
vious exposure to integrase inhibitors. Virological failure 
(VF) was defined as a confirmed HIV-RNA >50 copies/
mL (two consecutive values). We also investigated the 
risk of treatment failure (TF) defined as single HIV-RNA 
>200 copies/mL, intensification or discontinuation of 
DRV/r + RAL for any reason. Glomerular filtration rate 
was estimated using the CKD-EPI formula [16]. A range 
of methods were used to measure HIV-RNA according to 
availability at the participating sites. The most frequent 
were Real time Abbot PCR (n = 10, 13%), NASBA (n = 4, 
6%) and Roche (n = 3, 4%).
We performed time to event estimates using Kaplan–
Meier curves and Cox regression models. Covariates in the 
final model included the number of failures on regimens 
containing a PI, gender, mode of HIV transmission, HBV/
HCV co-infection, calendar year of switch, age, CD4 nadir 
count, CD4 count at cART initiation, viral load at cART 
initiation and duration of viral suppression <50 copies/mL.
Results
Seventy-two patients were included: 22 (31%) female, 
31 (43%) MSM, 15 (21%) had hepatitis co-infections (10 
with HCV and 5 with HBV). Median baseline characteris-
tics were age 44 [Interquartile range (IQR) 35–50] years, 
CD4 cell count was 389/mmc (IQR 283–606); HIV-RNA 
at initiation of cART was 4.22 (IQR 2.92, 6.54)  log10 cop-
ies/mL and total median duration of HIV-RNA ≤50 copies/
mL 5 months (IQR 1–53). Time from initiation of previous 
ART was 3 (IQR 1–30) months and median time from first 
starting antiretrovirals to the switch to DRV/r + RAL was 
10 months (IQR 1–109). Seventy-four (88.9%) patients 
were receiving a boosted PI at baseline and 14 (19%) 
patients previously failed virologically a PI-based cART 
before baseline. On average participants have been previ-
ously exposed to two lines of treatment (IQR 1–5), for 65% 
the dual regimen was the 4th therapy started. Forty-eight 
of the 72 patients (67%) were already receiving darunavir/r 
prior to switching to the dual regimen. Thirty-one (43%) 
patients switched from a 2 NRTI-including triple cART, 35 
(49%) from a PI monotherapy, 3 (4%) from a NRTI + PI/r 
regimen and 3 (4%) from other NRTI-including regimens.
Median total cholesterol levels were 180 (IQR 155–224) 
mg/dl, HDL 45 (IQR 35–54) mg/dl and triglycerides 106 
(IQR 75–156) mg/dl. Complete baseline patients charac-
teristics are shown in Table 1. The median follow-up time 
for the composite endpoint was 24 (IQR 9–31) months. The 
median follow-up time by gender was 24.5 months (IQR 
12–31) in males and 17.5 (5–33) in females. The proportion 
of people with at least 24 months of follow-up was 27/50 
(54%) among males and 10/22 (45%) among females.
Overall, we observed 30 discontinuation events of the 
dual regimen. However, regimen simplification in terms of 
pill burden was the most frequent cause of discontinuation 
and occurred in 15 out of 30 patients (50%), 14 of whom 
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discontinued RAL, whereas toxicity-driven interruption 
occurred only in 3 (10%) cases (1 lipid elevation, 1 renal and 1 
central nervous system toxicity). The remaining causes of dis-
continuations included patients’ decision in 2 (7%) and drug–
drug interactions, compliance with guidelines, virological 
failure, immunological failure, regimen intensification, death, 
temporary stop (physician’s decision) in 1 (3%) case each. In 
2 (7%) patients the cause of discontinuation was unknown.
Table 2 shows the number of patients experiencing 
VF and TF and the Kaplan–Meier estimates by 12 and 
24 months, respectively, for each of the adopted endpoints. 
The probability of VF defined as confirmed VL >50 cop-
ies/mL was 7% [95% confidence interval (CI) 1–13%] by 
12 months and 9% (95% CI 2–16%) by 24 months. When 
considering the composite endpoint of TF we found a 
probability of stop/intensification and single value of VL 
>200 copies/mL of 13% (95% CI 1–17%) and 22% (95% 
CI 11–33%) by 12 and 24 months, respectively.
Still considering the composite TF endpoint defined as 
stop/intensification and single value of VL >200 copies/
Table 1  Baseline 
characteristics of 72 patients 
with HIV RNA <50 cp/
ml switching to darunavir/
ritonavir + raltegravir
Data are expressed as median and interquartile range (IQR) or number (%)
RAL raltegravir, DRV darunavir, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside 
reverse transcriptase inhibitors, PI protease inhibitor, eGFR estimated glomerular filtration rate (CKD-EPI 
formula), HDL high-density lipoprotein, cART combination antiretroviral therapy
*Hepatitis C or Hepatitis B co-infection
Characteristics Total N = 72
Gender, n (%)
 Female 22 (30.6%)
Mode of HIV Transmission, n (%)
 IDU 8 (11.1%)
 Homosexual contacts 31 (43.1%)
 Heterosexual contacts 30 (41.7%)
 Other/unknown 3 (4.2%)
Hepatitis co-infection*, n (%) 15 (20.8%)
Calendar year of starting dual RAL/DRV 2012 (2011, 2013)
Age, years 44 (35, 50)
CD4 count at starting dual RAL/DRV, cells/mmc 389 (283, 606)
ALT at starting dual RAL/DRV, UI/L 20 (17, 28)
AST at starting dual RAL/DRV, UI/L 24 (9, 117)
Viral load at initiation of cART, log10 copies/mL 4.22 (2.92, 6.54)
Follow-up for composite outcome, months 24 (9, 31)
Time from ART initiation to start of dual RAL/DRV, months 10 (1, 109)
Type of cART in use prior to switch, n (%)
 PI/r 64 (88.9%)
  Darunavir/r 48 (66.7%)
  Atazanavir/r 10 (13.9%)
  Lopinavir/r 6 (8.3%)
 NNRTI 5 (6.9%)
  Efavirenz 2 (2.8%)
  Nevirapine 3 (4.2%)
  Other 3 (4.2%)
Previously virologically failed a PI 14 (19.4%)
Time with VL ≤50 before switch to RAL/DRV, months median (IQR) 16 (1, 63)
CD4 nadir, cells/mmc 236 (102, 341)
CD4 at time of starting cART, cells/mmc 371 (237, 536)
eGFR at starting dual RAL/DRV, mL/min/1.73m2 92 (70, 109)
Cholesterol at starting dual RAL/DRV, mg/dL 180 (155, 224)
HDL at starting dual RAL/DRV, mg/dL 45 (35, 54)
Triglycerides at starting dual RAL/DRV, mg/dL 106 (75, 156)
Time from initiation of previous cART, years 1 (1, 29)
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mL, from fitting a multivariable Cox regression analysis, 
female gender (adjusted relative hazard, ARH = 0.10; 95% 
CI 0.01, 0.74, p = 0.024) and older age (AHR = 0.50 per 
10 years older; 95% CI 0.25–0.99, p = 0.045) were associ-
ated with a lower risk of TF. Having previously experienced 
virological failure to a PI-based regimen was the strongest 
predictor of failure of the dual strategy (AHR = 52.6, 95% 
CI 3.6–779, p = 0.004). In contrast, viral load at starting 
cART, CD4 cell nadir and hepatitis coinfections were not 
associated with increased risk of TF (Table 3).
Historical genotypes were available for 47/72 (65%) 
patients. When looking at the virological endpoint of time 
to a single VL >200 copies (part of the composite outcome) 
those with major IAS PI resistance mutations (2/5, 40%) 
showed a higher risk of failure compared to those without 
(8/34, 19%) but the difference was not statistically signifi-
cant (Chi square p = 0.28). The univariate Hazard ratio 
(HR) for failure from fitting a univariable Cox regression 
model was 2.12 (95% CI 0.80–5.66, p = 0.13) for those 
with PI resistance vs. no PI resistance detected.
When looking at the endpoint of confirmed VL >50 cop-
ies/ml results were similar with patients with major PI 
resistance mutations (2/5, 40%) showing an increased risk 
of failure compared to those without (6/42, 14%, p = 0.15). 
Table 2  Number of patients experiencing virological failure (VF) and treatment failure (TF) and the Kaplan–Meier estimates by 12 and 
24 months
a
 First of two consecutive VL values
Endpoint 12 months 24 months
No. events Point estimate (%) 95% CI (%) No. events Point estimate (%) 95% CI (%)
Pure virological failure (VF)
Confirmeda VL >50 copies/mL 5 7 1–13 6 9 2–16
Treatment failure (TF)
Single VL >200 copies/mL or stop/intensification 9 13 1–17 13 22 11–33
Table 3  Relative Hazard of 
single VL >200 cp/mL or stop/
intensification
IDU injection drug users, RAL raltegravir, DRV darunavir, PI protease inhibitor
*Hepatitis C or Hepatitis B co-infection
Unadjusted and adjusted relative hazards of single VL >200 or stop/
intensification
Unadjusted RH (95% CI) p value Adjusted* RH (95% CI) p value
Gender
 Female vs. male 0.31 (0.11, 0.89) 0.029 0.10 (0.01, 0.74) 0.024
Mode of HIV transmission
 Homosexual contacts vs. IDU 0.98 (0.22, 4.33) 0.984 0.64 (0.08, 5.25) 0.675
 Heterosexual contacts vs. IDU 0.51 (0.11, 2.41) 0.395 0.52 (0.05, 5.51) 0.584
Hepatitis co-infection*
 Yes vs. No 1.06 (0.40, 2.80) 0.907 0.47 (0.10, 2.26) 0.345
Calendar year of starting dual RAL/DRV
 Per more recent 1.18 (0.87, 1.59) 0.294 1.78 (1.07, 2.95) 0.025
Age
 Per 10 years older 0.78 (0.58, 1.04) 0.089 0.50 (0.25, 0.99) 0.045
CD4 count nadir
 Per 100 cells higher 1.07 (0.84, 1.35) 0.595 0.83 (0.49, 1.42) 0.499
CD4 count at starting cART
 Per 100 cells higher 1.07 (0.93, 1.22) 0.343 1.19 (0.88, 1.62) 0.259
Viral load at starting cART
 Per log10 copies/mL higher 1.22 (0.95, 1.56) 0.114 0.92 (0.54, 1.59) 0.777
Time with VL ≤50
 Per 6 months longer 0.97 (0.89, 1.06) 0.543 0.89 (0.75, 1.05) 0.165
Previously failed a PI
 Yes vs. no 1.65 (0.62, 4.36) 0.316 52.57 (3.55, 779.0) 0.004
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The univariable HR for virological failure was 2.95 (95% 
CI 1.03–8.27, p = 0.04).
Mean (SD) CD4 count were 471 (164) cells/mm3 by 
3 months, 518 (213) 6 months, 552 (194) 9 months, 533 
(203) by 12 months and 599 (108) by 24 months.
With regards to tolerability, we did not find any signifi-
cant modification of total cholesterol, high-density lipopro-
teins (HDL), triglycerides, eGFR and alanine transaminase 
(AST) levels over 24 months (Fig. 1).
Discussion
Current guidelines suggest the use of a combination of 
three antiretroviral drugs as initial therapy, including 2 
NRTIs plus 1 PI/r, 1 integrase inhibitor or 1 NNRTI [8–
11]. However, taking into account the rising evidence of 
nucleoside analogues long-term toxicity, NRTI-sparing 
strategies are being used in clinical practice.
We showed that, in an unselected patient population, 
representative of the clinical practice setting in Italy, a 
dual therapy including DRV/r + RAL seems to be mod-
erately effective and tolerated over an average follow-up 
of 2 years. We found a relatively low probability of VF 
(considering both confirmed VL >50 or single value of 
VL >200 copies/mL) ranging between 9 and 15% by 
24 months from the time of switch. When we compared 
our results with those of the study by Calza et al. in a 
similar patient population we found higher rates of pure 
virological failure at 48 weeks (7 vs 2.4%). However, 
it should be considered that in the study by Calza et al. 
patients with previous failure to PI containing regimens 
were excluded thus probably explaining the observed dif-
ference [15].
When considering the composite outcome of TF we 
observed a probability of 13 and 22% of failure at 12 and 
24 months for the conservative definition of a single value 
of VL >200 copies/mL and stop/intensification. This result 
is in line with previous observational data on triple therapy 
in the observational cohort studies [17, 18].
Female gender and older age were independently associ-
ated with significantly lower risk of TF. It is possible that at 
least older age could represent a marker of better adherence 
[19, 20].
Contrary to what was found in PI/r monotherapy stud-
ies [21, 22], we did not find an increased risk of TF in 
Number of patients at each time point during follow up
Months 0 3 6 9 12 15 18 21 24
Triglycerides 70 18 10 18 14 17 9 10 12
HDL Cholesterol 68 18 10 18 14 17 9 10 12
eGFR 71 20 10 18 14 18 10 10 12
Total Cholesterol 70 18 10 18 14 17 9 10 12
ALT 72 20 10 18 14 18 9 10 12





















Fig. 1  Laboratory markers during follow-up (mean values at various time points from the date of switching to dual). HDL high-density lipopro-
teins (mg/dL), eGFR estimated glomerular filtration rate (CKD-EPI formula), ALT alanine transferase (UI/L)
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patients with shorter duration of viral suppression, low 
nadir CD4 and with hepatic co-infections, suggesting that 
DRV/r + RAL might be used safely by a larger proportion 
of individuals. Having previously failed a PI-based regimen 
was strongly associated with TF. Furthermore, we showed 
that the presence of major IAS PI resistance was associ-
ated with an increased HR of virological failure, especially 
when considering a confirmed VL >50 copies/mL. There-
fore, a previous failure of a PI-based regimen, especially 
if major IAS PI resistance mutations are detected, should 
remain a main limiting factor when selecting people for 
this strategy.
Our results also suggest that RAL + DRV/r is generally 
safe with a probability of discontinuation due to adverse 
events of 10% by 2 years.
We showed no significant modification in lipid profile 
whereas Calza et al. evidenced a significant reduction in tri-
glyceride levels after 48 weeks [15]. However, in that study, 
baseline mean triglyceride values were above the normal 
range (286 mg/dL) compared to our patients that showed 
a median of 106 (IQR 75–156) mg/dl. Since our patients 
started from normal levels no further benefit was expected 
and our data suggest that the combination of DRV + RAL 
was not associated with a worsening in lipid profile.
Our results also showed a non-significant modification 
of eGFR during 24 months of follow-up as also suggested 
by Calza et al. and highlight the renal tolerability of the 
combination [15].
Our data also showed a trend to increase in CD4 cell 
count over time which is in line with the significant 
increase shown by Calza et al. at 48 weeks [15]. However, 
since only a few patients had available data at each follow-
up time, we think it is fair to say that bigger studies are 
needed to confirm this result.
Most regimen discontinuations were due to treatment 
simplification (15, 50%) and twice daily RAL was the 
drug stopped probably due to the fear of selected non-
adherence to one of the two daily doses. However, only a 
minority of discontinuations was due to virological fail-
ure (1, 3%) and toxicity (3, 10%) over 2 years. Adherence 
is a complex phenomenon that implies acceptance of the 
diagnosis and motivation to carry out the treatment, pos-
session of appropriate skills and the ability to overcome 
any difficulties that appear to maintain the level of treat-
ment success over time. In patients with multiple previ-
ous cART regimen tolerability may favor adherence more 
than the daily schedule. Although once daily dose is the 
goal to improve adherence, it is not always superior to 
twice daily dosing in terms of virologic success. In fact 
Nachega et al. evidenced that once daily therapy is asso-
ciated with better adherence but not with better virologic 
results in a systematic review of 19 clinical trials [23]. 
Another recent study by Arroyo et al. found no difference 
in adherence rates in patients receiving once or twice 
daily regimens [24]. A French study showed that non-
adherence was independently associated with side effects, 
and having a three times or more daily dosing regimen in 
comparison to once or twice daily therapy [25].
The upcoming availability of 1200 mg once daily RAL 
and the present possibility to use co-formulated DRV/Cobi-
cistat could represent a future advantage of the combina-
tion of DRV + RAL in virologically suppressed patients.
The main limitation of our analysis is the lack of a 
control group to compare the failure estimates of the dual 
DRV/r + RAL regimen to that of a standard triple cART. 
In particular, it is not obvious to set a threshold below 
which the proportion of failure of this strategy is too high 
to be acceptable (compared to remaining on triple regi-
mens for example). In this case even the historical con-
trols are not fully comparable as performed in the context 
of first-line cART. Furthermore, since only a half of the 
patients were switched from NRTI-including cART to 
DRV/r + RAL, this study cannot evaluate the potential 
advantages of switching from a NRTI-including to a dual 
NRTI-sparing regimen.
In conclusion, switching to DRV/r + RAL in clini-
cal practice is a valuable NRTI-sparing regimen, with 
a relative low risk of VF (7–9%) and good tolerability 
after 2 years since start in an antiretroviral-experienced 
population. Of note, female and older patients, both vul-
nerable populations, seem to have greater benefits from 
this strategy. Larger studies are needed to establish more 
solid criteria for selecting people who might benefit from 
this dual regimen but previous failure of a PI-based ART 
should represent a limiting factor for this strategy.
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